

AWARD NUMBER: W81XWH-16-1-0119

TITLE: Understanding the Immune-Biology of Checkpoint Inhibitors to Develop New Strategies for Therapy

PRINCIPAL INVESTIGATOR: Meenhard Herlyn

CONTRACTING ORGANIZATION: The Wistar Institute of Anatomy & Biology ,Philadelphia, PA 19104

REPORT DATE: October 2019

TYPE OF REPORT: Annual

PREPARED FOR:

**U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE Oct 2019		2. REPORT TYPE Annual		3. DATES COVERED 09/30/2018-09/29/2019	
4. TITLE AND SUBTITLE Understanding the Immune-Biology of Checkpoint Inhibitors to Develop New Strategies for Therapy				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-16-1-0119	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Meenhard Herlyn E-Mail: herlynm@wistar.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Wistar Institute 3601 Spruce Street Philadelphia, PA 19104-4265				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES N/A					
14. ABSTRACT This proposal deals with the development of novel treatment strategies for the deadliest of all skin cancers, melanoma. The disease is generally caused by excessive ultraviolet light (sun) exposure. Once the tumor cells have spread from the skin to other organs, there is only a ~15% chance of surviving more than five years. This may change because in the last five years seven new treatments have been approved by the Food and Drug Administration, each improving survival of patients and/or their well-being. The clinical and scientific evidence clearly points to the potential for further improvements in treatment outcome, mainly by combining different drugs. The core of the proposal is a clinical trial for the treatment of advanced melanoma, in which two newly-approved drugs are tested in combination when compared to the stronger drug alone. Now we need to extract as much information as possible from the trial by monitoring the blood and tumor before and during treatment and, in case the patients become resistant and progress with disease, after therapy. Ideally, we want to combine the stimulation of the immune system with new inhibitors that block MAPK signaling pathways in the cancer cells, but the initial studies done by others had to be stopped due to toxicities from the treatment. While we can progress in developing new strategies in patients, we need to advance faster. Therefore, we want to do all initial treatment work in experimental animals. To date, this has been difficult because the animal models do not faithfully reflect the human disease and, if they do, important components such as the immune (defense) system are missing. We have now developed two novel models of cancer, in which mice bear the human cancer cells but at the same time have a human immune system that is developed from blood stem cells. One model uses immune stem cells from newborns and the other uses stem cells from the same patients we have obtained tumors from. These models will allow us to investigate the mechanisms of tumor destruction (response) and tumor progression (resistance) by the drugs and also to develop novel rationale-guided combination therapies with a variety of drugs.					
15. SUBJECT TERMS BRAF, CTLA4, humanized mice, immune-checkpoint, immunodeficient, immune response, inhibitors, Ipilimumab, MAP kinase targeted-therapy, MEK, Nivolumab, program cell death (PD1), patient-derived xenograft (PDX).					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER 11	19a. NAME OF RESPONSIBLE PERSON
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18

TABLE OF CONTENTS

	<u>PAGE</u>
1. INTRODUCTION.....	4
2. KEYWORDS.....	4
3. ACCOMPLISHMENTS.....	4
4. IMPACT.....	7
5. CHANGES/PROBLEMS.....	8
6. PRODUCTS.....	9
7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS.....	10
8. SPECIAL REPORTING REQUIREMENTS.....	10
9. APPENDICES.....	11

1. INTRODUCTION:

Our long-term objective is to improve therapy outcome in melanoma. In the last few years, therapeutic responses in melanoma patients has considerably improved by using both targeted-therapies (signaling inhibitors) and immune-based therapies (anti-CTLA4 and anti-PD1 antibodies [immune checkpoints inhibitors]). BRAF inhibitor either alone or in combination with MEK inhibitor provided rapid clinical responses in patients; however, the therapy is applicable to ~50% of patients who carry the BRAFV600E mutation. Moreover, the responses are short-lived due to rapid development of acquired resistance. In contrast, clinical responses to immune-based (anti-CTLA4 or anti-PD1) therapies are slower but more durable targeting a broader cohort of melanoma patients. Recent reports, suggest that combined targeting of PD1 and CTLA4 provides synergy and more enhanced duration of clinical responses. This is the basis of our current ongoing clinical trial combining anti-PD-1 (Nivolumab [Nivo]), with anti-CTLA4 (Ipilimumab [Ipi]) at the MD Anderson Cancer Center. The trial, which is independently funded, provides the backbone of this collaborative grant between MD Anderson and The Wistar Institute with additional interactions with the University of Pennsylvania. Our overall objective is to combine targeted and immunotherapy to eradicate all malignant cells at the time of initial treatment because in each therapeutic strategy, a subpopulation of malignant cells can survive and subsequently develop acquired resistance. While in-depth molecular mechanisms of intrinsic and acquired resistance to BRAF and MEK signaling inhibitors in melanoma are known, very little information is available on why checkpoint inhibitors are active only in a subset (~25-30%) of patients, the cause of therapy non-responsiveness or resistance, or how to modify the immune response for achieving the highest therapeutic efficacy. In this collaboration, we are focusing on research efforts on mechanisms of action of checkpoint inhibitors *in vivo* to understand how we can optimally apply and translate them in patients and how we can use them in the future for designing combination studies that are rationale-based and personalized.

2. KEYWORDS:

BRAF, CTLA4, humanized mice, immune-checkpoint, immunodeficient, immune response, inhibitors, Ipilimumab, MAP kinase targeted-therapy, MEK, Nivolumab, program cell death (PD1), patient-derived xenograft (PDX).

3. ACCOMPLISHMENTS:

- **Major goals of the project.**

We incorporated a clinical trial into the study and compare the data from the trial with those in humanized mice. Thus, in Aim 1 we collect specimens from tumor and blood to monitor patients and provide material for experimental studies including the production of patient-derived xenografts (PDX).

In Aim 2 we proposed to develop new experimental models to investigate human immune responses to tumors. We proposed to develop two models, an HLA-matched model, in which the mice receive hematopoietic stem cells from either cord blood or fetal liver and then monitor the immune response to human melanoma; in the second model, we are taking blood from

patients to create induced pluripotent stem cells (iPS cells) that we can in turn differentiate to blood cells. This model was not complete yet and needed further fine tuning.

In Aim 3 we investigate the immune mechanisms and compare the data in patients with those in mice.

For Aim 1,

Major task 1: Obtain approvals and initiate collection of patient samples.

1. Local IRB/IACUC approvals from Wistar has been completed.
2. HRPO approvals from DOD has been completed.
3. Twenty patients each from Nivo alone and Nivo + Ipi were planned from recruitment (see below on number of patients collected so far for each treatment arm).

Major task 2: Collection and analysis of patient tumor and blood samples.

(Please refer to Annual report submitted independently by MD Anderson).

For Aim 2,

Major task 2: Obtain PDX use approvals and select PDX to be used for model development.

1. Wistar IRB approval for use of patient tumor and blood samples for PDX usage were obtained (Protocol #2802240 [use of human melanoma tissues] approved and renewed on 16th July 2019 and Protocol # 21602279 was approved and renewed on April 1st, 2019.
2. IACUC approval for PDX inoculation continuation was approved on May 3rd, 2019.
3. HRPO and ACUORO approval/renewal request was submitted on July 2019.

- **What was accomplished under these goals?**

Specific Aim 1. Bio specimens and monitoring. MD Anderson will provide updated information on a new trial in their Annual report. Original trial was closed due to high grade toxicities for combination therapy arm (Ipi + Nivo) and the low response to single agent Nivo arm. We have received 60 tumor specimens from 22 patients have been delivered to Wistar since June 1, 2016 for PDX generation. Amongst the 22 patients delivered to Wistar 12 of them are treated with PD1 (Nivo) therapy (1 patient received treatment off study) and 10 were treated with Nivo + CTLA4 (Ipi) therapies. Twenty PDX are established, 37 specimens failed, and 6 specimens are in the process of establishment and too soon to determine their status of establishment. For iPS production, 11 blood samples were received.

Specific Aim 2 (humanization of mice), we have injected 48 batches of 40 to 60 mice (each




Fig. 2. Heterogeneous distribution of CD8+ Granzyme B+ cells, downmodulation of HLA-class I and increase in FOXP3+ cells in tumors after anti-PD-1 therapy.






Fig. 1. a. Schema for anti-PD-1 therapy in Hu-mice. b. Mixed anti-PD-1 therapy response in established tumor model of Hu-mice. Two different batches of Hu-mice were challenged with HLA-A2 or HLA-A3 melanoma cells and followed with anti-PD-1 injections every 5 to 6 days for a total of 6 injections. Mixed therapy responses to anti-PD-1 was observed.


CD8, Nestin




Nestin, HLA class I




HLA class I




CD8, Nestin, HLA class I



CD8, Granzyme B



CD4, FOXP3




batch) with CD34+ cells derived from fetal liver. We have completed therapy experiments with anti-PD-1 in 8 batches. We observed mixed responses to anti-

PD-1 and none of the treated-tumor bearing Hu-mice showed complete regression (**see Fig. 1**). To understand the mechanism of resistance, tumor sections were examined by multiplex imaging using MassCyTOF and RNA seq studies. We found heterogeneous distribution of CD8+ T cell infiltration, down-modulation of HLA class I molecules, and increased presence of

FOXP3+ T cells and mast cells in areas where tumor cells survived (see Figs. 2 and 3). We have analyzed RNASeq dataset from Dr. Jen Wargo's clinical trials and the results showed that there is an increased number of mast cells in non-responders to immune-checkpoint therapy antibodies (see Fig. 4). Mast cells are generally c-kit+ and we have targeted them by using

Mast Cells Co-express CXCR3



Mast Cells and HLA Class I Downmodulation




Fig 3. Mast cells co-express CXCR3 (left panel) and tumor cells secrete CXCL10 a ligand for CXCR3 and this results in attraction of mast cells to the tumor area. Mast cell infiltration causes HLA class I downmodulation (right panel).




Fig. 4 Increased number of mast cells in immune-checkpoint therapy non-responders.

Sunitinib. Treatment of tumor-bearing Hu-mice by Sunitinib alone did not show restriction of tumor growth. However, a combination of Sunitinib and anti-PD-1 showed complete regression of tumors (see Fig. 5). Cured Hu-mice were given a drug holiday for 4 weeks and then re-challenged with fresh tumors. None of the tumors grew for 4 weeks to indicate there is a memory T-cell response that rejects freshly implanted tumors. We have repeated the experiment using a combination of Imatinib (targeting c-kit+ cells) and anti-PD-1. As in Sunitinib study, we observe complete regression of

tumors (see Fig. 5). One another drug, Cediranib not so specific for c-kit but targeting VEGFR and PDGFR was included in the study and the tumors continued to grow (see Fig. 5). We have sequenced the T-cell receptors (TCR) from tumor infiltrating cells and found that sequences matched to TCR reactive to melanoma differentiation antigen (MART). We have submitted a




Fig. 5. Complete regression of tumors after combination of sunitinib and anti-PD therapy. Established tumors in Hu-mice were treated with sunitinib (20mg/kg) daily by oral gavage and after 72 h, anti-PD-1 therapy (10 mg/kg) was given weekly for a total of 6 injections. Complete tumor regression was observed in presence of combination therapy (black inverted triangle; $p < 0.0001$; 2nd panel), while sunitinib alone (grey circles), anti-PD-1 alone (blue line, closed circles) or control IgG (magenta; open circles) did not have any effect of tumor growth. We observed similar results when drug Imatinib (50mg/kg; daily by oral gavage) was used in combination with anti-PD-1 (brown line, closed circles; $p < 0.001$; 3rd panel from the bottom). Imatinib alone had no effect on tumor growth. Cediranib (6mg/kg; daily by oral gavage) either alone or in combination with anti-PD-1 antibody was unable to shrink the tumors (bottom panel). f. Survival curve from the above treated mice indicates significant ($*p < 0.0001$) survival advantage of tumor bearing Hu-mice that received combination therapy of sunitinib and anti-PD-1 group when compared to sunitinib alone (grey), or anti-PD-1 alone (dark blue) or control IgG (magenta) groups.

response letter to Reviewers' comments, and we are waiting for the Nature Journal Editor to give us an approval to submit the revised manuscript. We have planned combination therapy with signaling inhibitors (BRAF) and anti-PD-1. We have made enormous progress with the iPS model (subtasks 5 and 6). Several batches of CD34+ cells derived from iPS has been injected into mice directly into the tail vein or into the femoral bone for better lymphocyte reconstitution. We consistently observe increased presence of CD45+ cells in the non-injected bone and in the mouse peripheral blood. However, percentage of CD45+ cells in circulating blood is still low. We have successfully adapted a new rapid expansion of CD34+ cells (10-fold increase) *in vitro* by use of valproic acid, a pan HDAC inhibitor, and growth factors. We have injected *in vitro* expanded CD34+ cells into several NSG mice for lymphoid cell reconstitution. This will help us increase the number of animals for humanization. We also injected iPS generated hepatocytes as a source of CD34+ cells. Recently completed, RNAseq study of fetal liver and iPS-hepatocytes reveals close match with many common hepatocyte markers on iPS-derived cells. We have constructed several lenti-viral based transcription factors for transduction into CD34+ cells to enhance the speed of differentiation into lymphoid cells. We have successfully labeled CD34+ cells with mCherry CD45 promoter construct for tracing the CD34+ cell differentiation. Currently, CD34+ cells transduced

with mCherry CD45 promoter is used for screening the transcription factors that promote lymphoid cell differentiation. George Xu continues to offer histology staining support.

- **What opportunities for training and professional development has the project provided?**

Nothing to Report.

- **How were the results disseminated to communities of interest?**

Nothing to Report.

- **What do you plan to do during the next reporting period to accomplish the goals?**

We will continue to work on the 1st model (HLA matched) to test the efficacy of combination of signaling inhibitors and anti-PD-1 therapies.

We will continue our effort in improving and establishing the 2nd model with use of iPS derived CD34+ cells.

4. IMPACT:

- **What was the impact on the development of the principal discipline(s) of the project?**

Nothing to Report.

- **What was the impact on other disciplines?**

Nothing to Report.

- **What was the impact on technology transfer?**

Nothing to Report.

- **What was the impact on society beyond science and technology?**

Nothing to Report.

5. CHANGES/PROBLEMS:

- **Changes in approach and reasons for change**

Nothing to report.

- **Actual or anticipated problems or delays and actions or plans to resolve them**

Nothing to report.

- **Changes that had a significant impact on expenditures**

Nothing to report.

- **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

Nothing to report.

- **Significant changes in use or care of human subjects**

Nothing to report.

- **Significant changes in use or care of vertebrate animals.**

Nothing to report.

- **Significant changes in use of biohazards and/or select agents**

Nothing to report.

6. PRODUCTS:

Nothing to Report.

- **Publications, conference papers, and presentations**

Study from Aim 2 is waiting for Nature Editor's approval for 1st revised submission.

- **Website(s) or other Internet site(s)**

Nothing to report.

- **Technologies or techniques**

Nothing to report.

- **Inventions, patent applications, and/or licenses**

Nothing to report.

- **Other Products**

Establishment of humanized mouse melanoma model.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

- **What individuals have worked on the project?**

Name:	Meenhard Herlyn
Project Role:	Principal Investigator
Researcher Identifier (e.g. ORCID ID):	N/A
Nearest person month worked:	0.6 cal month
Contribution to Project:	Project planning and coordination.
Funding Support:	This award

Name:	Vito Rebecca
Project Role:	Staff Scientist
Researcher Identifier (e.g. ORCID ID):	N/A
Nearest person month worked:	1.2 cal month
Contribution to Project:	Establishment of PDX.
Funding Support:	This award

Name:	Rajasekharan Somasundaram
-------	---------------------------

Project Role:	Research Assistant Professor
Researcher Identifier (e.g. ORCID ID):	N/A
Nearest person month worked:	4.8 cal month
Contribution to Project:	Humanized model #1. Supervision of technicians.
Funding Support:	This award
Name:	Min Xiao
Project Role:	Research Assistant IV
Researcher Identifier (e.g. ORCID ID):	N/A
Nearest person month worked:	3.0 cal month
Contribution to Project:	Growth of PDX.
Funding Support:	This award

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

Nothing to Report.

- **What other organizations were involved as partners?**

Nothing to report.

8. APPENDICES:

None